VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $1.17 Million Investment in Repligen Corporation $RGEN

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 8,600 shares of the biotechnology company’s stock, valued at approximately $1,173,000.

A number of other hedge funds have also recently made changes to their positions in the business. California State Teachers Retirement System lifted its holdings in shares of Repligen by 13,158.5% in the 2nd quarter. California State Teachers Retirement System now owns 8,201,681 shares of the biotechnology company’s stock worth $1,119,037,000 after acquiring an additional 8,139,821 shares during the last quarter. Angeles Wealth Management LLC grew its holdings in shares of Repligen by 6.6% during the 2nd quarter. Angeles Wealth Management LLC now owns 2,757 shares of the biotechnology company’s stock valued at $376,000 after purchasing an additional 170 shares during the last quarter. Nykredit A S purchased a new position in Repligen in the 2nd quarter worth $269,000. B. Metzler seel. Sohn & Co. AG raised its position in Repligen by 52.8% in the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 26,361 shares of the biotechnology company’s stock worth $3,597,000 after purchasing an additional 9,108 shares during the period. Finally, Moore Capital Management LP bought a new stake in Repligen in the second quarter worth $5,123,000. 97.64% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CFO Jason Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Zacks Research upgraded shares of Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Wolfe Research initiated coverage on Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price for the company. HSBC dropped their target price on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. UBS Group raised their price target on Repligen from $195.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Citigroup raised Repligen to a “buy” rating in a research note on Tuesday, July 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $168.57.

Repligen Stock Performance

NASDAQ:RGEN opened at $165.18 on Friday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The firm’s fifty day simple moving average is $158.22 and its 200 day simple moving average is $135.29. The stock has a market cap of $9.32 billion, a P/E ratio of 226.27, a price-to-earnings-growth ratio of 3.01 and a beta of 1.05. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $188.73.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same period in the prior year, the business earned $0.26 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, research analysts predict that Repligen Corporation will post 2.06 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company’s portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.